- Apr 20, 2018
Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug...
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Cytokinetics and Astellas Pharma's reldesemtiv for the treatment of amyotrophic lateral sclerosis (ALS), the companies announced. Reldesemtiv, a fast skeletal muscle troponin activator designed to improve muscle...
Moderators: Is it acceptable to post these articles? I know there are rules, so remove if necessary.
So can the wiser ones among us please explain "Now what?" What happens next at this stage of orphan status? What else do those of you with other knowlege know about this drug?
At what point do I (or others of us) contact our neurologist and inquire about it? Or other drugs making progress?